Pulmonx (NASDAQ:LUNG) Bolsa

PULMONX CORP

Pulmonx

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Pulmonx Corp

News

Legal

ARGT

Reuters Reports U.S. Judge Orders Argentina To Transfer 51% Stake In Oil And Gas Company YPF, To Partially Satisfy $16.1B Judgment

Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6).
The study met its primary endpoint of overall survival (OS) at a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n46167179/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-rec" rel="noreferrer noopener">pre-specified interim analysis</a>.&nbsp;
Bemarituzumab plus chemotherapy demonstrated a&nbsp;statistically significant and clinically meaningful improvement in OS as compared to&nbsp;placebo plus chemotherapy for unresectable locally advanced or&nbsp;metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b&nbsp;overexpression and who are non-HER2 positive.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46081494/analyst-views-mixed-as-amgens-weight-loss-diabetes-drug-maritide-shows-promise-but-has-dose-issues" rel="noreferrer noopener">Analyst Views Mixed As Amgen&#8217;s Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues</a>
Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year.
The most common treatment-emergent adverse events (&gt;25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anemia, neutropenia, nausea, corneal epithelium defect, and dry eye.
While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm. Detailed results from the trial will be shared at a future medical meeting.
FORTITUDE-101 was conducted with the support of Zai Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>). Zai Lab holds co-development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.
A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with a data readout anticipated in the second half of 2025.
Commenting on the Phase 3 results, William Blair stated, &#8220;We look forward to the detailed update to understand the survival benefit seen with bemarituzumab as well as the safety profile.&#8221;
Analyst Matt Phipps emphasized that the rates of ocular adverse events (AEs) and subsequent discontinuation of bemarituzumab will be critical data points for assessing the drug&#8217;s market potential.
He reiterated optimism for MariTide, stating, &#8220;We still see a differentiated product profile for MariTide versus currently approved GLP-1 therapies or those in late-stage development, and therefore potential for meaningful market share and a multibillion-dollar peak sales opportunity.&#8221;
Despite this, Amgen is navigating immediate challenges stemming from its established product portfolio and difficulties in expanding market share within its biosimilar franchises.
However, William Blair anticipates that upcoming clinical milestones within the next 6 to 12 months will generate significant investor enthusiasm regarding Amgen&#8217;s long-term growth trajectory. Consequently, the firm has maintained its Outperform rating for the company.
Price Action: AMGN stock is up 0.40% at $278.23 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/46036868/obesity-drugs-help-with-weight-loss-but-are-adding-fat-elsewhere" target="_blank" rel="noreferrer noopener">Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Analyst Color

Biotech

Large Cap

Health Care

Analyst Ratings

General

AMGN

ZLAB

Amgen's Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects

WIIM

PSTV

Plus Therapeutics shares are trading higher after the company announced the initiation of its ReSPECT-LM dose optimization trial for REYOBIQ.

NUKK

Nukkleus shares are trading higher amid its addition to the Russell Microcap index.

A Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) spot exchange-traded fund (ETF) with <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40470226/solana-etf-approval-in-2024-has-only-a-6-chance-a-snowballs-chance-in-hell-etf-analyst-say">staking support could debut</a> this week, according to Bloomberg ETF analyst James Seyffart. 
Seyffart's <a href="https://x.com/JSeyff/status/1939675595819946341">tweet </a>on Monday hinted at the imminent arrival of the product, adding weight to growing market expectations around Solana's regulatory approval in the United States.
The ETF, developed by REX Shares in partnership with Osprey Funds, is expected to offer U.S. investors exposure to Solana, while also providing staking rewards directly through the fund.
Branded as the REX-Osprey&#x2122; SOL + Staking ETF, the product is <a href="https://www.rexshares.com/rex-osprey-etfs/">positioned </a>to be the first staked crypto ETF in the U.S. market.
Polymarket traders appear to be increasingly confident that the ETF will be approved soon. 
As of Monday, the prediction market <a href="https://polymarket.com/event/solana-etf-approved-by-july-31-2025">showed</a> a 97% chance of a Solana ETF being approved by July 31, based on over $376,000 in total volume.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46168953/strategy-adds-4980-bitcoin-ups-total-stack-to-42-billion">Strategy Adds 4,980 Bitcoin, Ups Total Stack To $42 Billion</a>
The probability has surged by 47 points in recent days, according to Polymarket data.
The sharp rise in market confidence coincides with recent regulatory momentum following the approval of multiple spot Bitcoin ETFs earlier this year, and growing speculation that Ethereum and Solana-based ETFs could follow.
The REX-Osprey SOL + Staking ETF is set to offer investors yield-generating exposure by tracking Solana's price performance while also earning on-chain staking rewards, an industry-first combination for U.S.-listed ETFs.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46168111/bitcoin-options-traders-shift-bullish-heres-their-strategy-for-q3">Bitcoin Options Traders Shift Bullish: Here&#8217;s Their Strategy For Q3</a></li>
</ul>
Image: Shutterstock

$SOL

Solana ETF Approval Imminent As Odds Skyrocket To 97%

AIMD

Ainos shares are trading higher after the company completed its 1-for-5 stock consolidation.

PROK

ProKidney shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform and cut its price target from $3 to $1.

Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) has made a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g46172267/robinhood-launches-stock-tokens-reveals-layer-2-blockchain-and-expands-crypto-suite-in-eu-and-us-w" rel="noreferrer noopener">significant push into</a> crypto, unveiling a suite of innovative products during its event in Cannes, France. The company revealed a range of new tools designed to make investing more accessible and intuitive.
As part of its global expansion strategy, Robinhood is extending its services to over 400 million people across 30 countries in the EU and EEA. The stock gained after the update.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45155666/robinhood-stock-falls-after-analysts-cite-weak-crypto-volumes-and-market-headwinds-in-q2-outlook" rel="noreferrer noopener">Robinhood Stock Falls After Analysts Cite Weak Crypto Volumes And Market Headwinds In Q2 Outlook</a>
The new offerings include stock and ETF tokens, now available in the EU. These tokens allow users to gain exposure to U.S. equities through Robinhood Stock Tokens.
These tokens come with zero commissions and offer dividend support alongside 24/5 access.
With this launch, Robinhood&#8217;s European app transitions from a solely crypto-focused app to a comprehensive investment platform powered by crypto, marking a significant expansion.
Vlad Tenev, Robinhood&#8217;s chairman and CEO, emphasized the company&#8217;s aim to lay the groundwork for crypto to serve as the backbone of the global financial system. Additionally, Johann Kerbrat, GM and SVP of Robinhood Crypto, highlighted that crypto was initially built for engineers and hasn&#8217;t been easily accessible to most people. &#8220;We&#8217;re onboarding the world to crypto by making it as easy to use as possible,&#8221; said Kerbrat.
Robinhood has also introduced crypto perpetual futures to the EU, offering up to 3x leverage for eligible users. This launch is designed to provide active traders with more sophisticated tools in a user-friendly environment. Furthermore, the company is launching crypto staking in the U.S., beginning with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), allowing customers to participate in blockchain ecosystems and earn competitive rewards.
The expanded product suite includes features such as an instant boost on crypto deposits, a new credit card offering cashback that can be used to buy crypto, and a Cortex AI-powered assistant that helps users understand market trends. Smart Exchange Routing will also help users get the best price for crypto trades by evaluating multiple exchanges.
Additionally, Robinhood has unveiled its upcoming Layer 2 blockchain, built on Arbitrum. This blockchain will enable seamless trading and self-custody and power tokenized stocks and real-world assets in the future.
Robinhood Markets stock is up 131% year-to-date.
Robinhood reported <a href="https://www.benzinga.com/news/earnings/25/04/45118133/robinhood-q1-earnings-highlights-record-trading-volumes-transaction-based-revenues-up-77-gold-subscribers-up-90" target="_blank" rel="noreferrer noopener">first-quarter earnings</a> of 37 cents per share in April, which beat the analyst consensus estimate of 32 cents. Quarterly revenue of $927 million (up from $618 million a year ago) beat the analyst consensus estimate of $922.53 million.
Transaction-based revenues increased 77% to $583 million as Cryptocurrency revenue of $252 million ( up 100% Y/Y), Options revenue of $240 million (up 56% Y/Y), and Equities revenue of $56 million (up 44% Y/Y).
Price Action:&nbsp;HOOD stock is trading 10.5% higher at $91.82 as of last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/06/46149909/nvidia-ai-acquisition" target="_blank" rel="noreferrer noopener">Nvidia Is Acquiring Its Way Into AI</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

HOOD

Robinhood Just Made Crypto Simpler — And Way More Powerful

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

Faraday Future shares are trading higher after the company announced the debut of the FX Super One EAI-MPV.

Equitable Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>) has outperformed the market over the past 5 years by 9.44% on an annualized basis producing an average annual return of 23.65%. Currently, Equitable Holdings has a market capitalization of $17.14 billion. 
Buying $1000 In EQH: If an investor had bought $1000 of EQH stock 5 years ago, it would be worth $2,951.63 today based on a price of $55.96 for EQH at the time of writing.
<h3>Equitable Holdings's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751301912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

MDAI

Spectral AI shares are trading higher after the company announced it submitted a De Novo 510k marketing clearance application to the FDA for its DeepView System.

CSAI

Cloudastructure shares are trading higher after Maxim Group initiated coverage on the stock with a Buy rating and announced a price target of $6.

ALOT

AstroNova shares are trading higher. The company announced new senior leadership changes for its CEO and president.

UBS analyst Robin Farley maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Neutral and lowers the price target from $29 to $23.

Price Target

NCLH

UBS Maintains Neutral on Norwegian Cruise Line, Lowers Price Target to $23

In a move that will help satisfy increasing demand for globally diversified fixed income solutions, BlackRock launched the iShares Global Government Bond USD Hedged Active ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GGOV#NYSE">GGOV</a>), the industry&#8217;s first and only<a href="https://www.benzinga.com/etfs"> actively managed ETF</a> providing USD-hedged exposure to global government bonds.
The fund is billed as a game changer for fixed-income investors who wish to lower risk and pursue higher yields overseas, minus the headache of currency risk.
Also Read: <a href="https://www.benzinga.com/etfs/sector-etfs/25/06/46157240/runway-ready-can-aviation-safety-tech-be-the-next-frontier-for-aerospace-etfs">Runway Ready: Can Aviation Safety Tech Be The Next Frontier For Aerospace ETFs?</a>
The fund carries an expense ratio of 0.39%, and follows the Bloomberg Global Treasury USD Hedged Index as its benchmark.
Tom Becker, lead portfolio manager of GGOV, explained that USD-hedged global government bonds in the past have returned more with less volatility than similar U.S.-only bond indices. 
&#8220;We believe that GGOV will be an important tool for many U.S. asset allocators in the current environment of elevated inflation, large budget deficits, and rising issuance,&#8221; he added.
<h1 class="wp-block-heading">What Makes GGOV Different?</h1>
The ETF aims to solve an expanding sore point: overexposure to long-dated U.S. Treasuries, which most investors view as increasingly at risk in the face of fiscal turmoil. GGOV&#8217;s worldwide strategy, underpinned by a currency hedge, aims to increase yields and lower risk when U.S. interest rates outstrip international counterparts.
GGOV comes to the market at the right time when investors are reassessing their bond exposures following global rate changes and ongoing inflation. By blending active alpha creation with a USD hedge, BlackRock is designed to offer both defense and diversification.
GGOV also joins BlackRock&#8217;s growing empire of fixed income ingenuity as the newest member of its $52 billion U.S. active ETF platform and plays a part in its enormous $1 trillion global bond ETF franchise.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/06/46166959/sp500-stocks-outlook-etf-analysis">This S&amp;P 500 ETF Saw A 30-Month Buying Spree — Now It&#8217;s Over</a></li>
</ul>
Photo: Shutterstock

Bonds

New ETFs

Global

ETFs

GGOV

BlackRock Hedges Its Bets — Literally (ETF Included)

Shares of The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) were up by <a href="https://www.benzinga.com/markets/equities/25/06/46165400/boeing-rises-2-8-after-key-trading-signal">almost 6% Friday</a>. But trading on Monday is quiet. The stock has stalled out at an important resistance level.
‘Sell at former peaks' is an old saying on Wall Street. Boeing may prove it to be true once again, like it did earlier this month. This is why we have made it our <a href="https://www.benzinga.com/topic/stock-of-the-day">Stock of the Day</a>.
As you can see on the chart below, back in early 2024 Boeing spent a lot of time trading around $215. It was a resistance level. The sellers put a top on it, and then eventually drove it lower. When this happened, a number of traders and investors who bought shares around $215 decided that their decision to do so was a mistake.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="567" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30123319/one12-1024x567.png" alt="" class="wp-image-967272" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30123319/one12-1024x567.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30123319/one12-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30123319/one12-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/30123319/one12.png 1459w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/news/politics/25/06/46166058/elon-musk-birthday-trump-tax-bill-economy">Elon Musk&#8217;s Birthday Wish: Kill The Bill Before It Kills The Economy</a>
Some vowed to hold onto their losing positions. But they also decided that if they could ever do so, they would sell their shares at the same price they paid for them. This would allow them to exit their positions at breakeven.
Because of this, when the stock finally rallied back to $215 earlier this month these traders and investors came into the market as sellers. The large group of orders they placed caused there to be resistance around $215 again.
After the stock sold off of this level for a second time, a similar dynamic occurred.
Some of the people who bought around $215 developed buyer&#8217;s remorse when the price dropped. They also decided to sell if the price returned to their buy price. Now that Boeing has returned to this level, these traders have started to sell.
The large concentration of these sell orders has created resistance again.
‘Sell at former peaks' is a saying based upon the idea that when a stock returns to a price or a level that had previously been a peak or resistance, there is a good chance it hits resistance there again. There's also a good chance a selloff follows.
Shares of Boeing may be about to head lower.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46171994/emerging-markets-stocks-dollar-outlook">A Weaker Dollar Just Unlocked A Surprise 2025 Winner — And Smart Money Is Moving In</a></li>
</ul>
Image: Shutterstock

Technicals

Stock Of The Day: Will Boeing Prove An Old Wall Street Saying Is True?

BZAI

Blaize Holdings shares are trading higher after the company announced an approximate $56 million contract for its AI platform will be deployed across intelligence surveillance endpoints.

SoFi Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) shares hit a new 52-week high on Monday, capping a period of significant gains in June despite a quiet session for company-specific news. Here&#8217;s what investors <a href="https://www.benzinga.com/quote/SOFI/news">need to know</a>. 
What To Know: The fintech company's shares have been on an upward tear in June, fueled by recent strategic announcements and bullish growth forecasts.
Last week, SoFi <a href="https://www.benzinga.com/markets/tech/25/06/46117473/sofi-stock-gets-supercharged-with-return-to-crypto">revealed</a> its renewed push into the cryptocurrency space, announcing plans to allow members to trade digital assets like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) later this year. The initiative will also include offerings such as crypto-backed loans and international money transfers. 
CEO Anthony Noto emphasized that blockchain innovations would be integrated across all of SoFi's business lines, from investing and borrowing to daily payments.
This latest move builds on the <a href="https://www.benzinga.com/trading-ideas/movers/25/06/46030175/sofi-stock-rises-this-week-amid-bullish-guidance-whats-going-on">strong momentum</a> from earlier in June when executives reaffirmed aggressive growth projections. At the William Blair Growth Stock Conference, CFO Chris Lapointe projected adjusted net revenue to exceed $3 billion by 2025, with annual growth surpassing 25% through 2026.
Analyst Ratings: Analysts have offered a mixed but <a href="https://www.benzinga.com/quote/SOFI/analyst-ratings">generally constructive</a> view on SoFi&#8217;s stock in recent months. On June 2nd, Truist Securities initiated coverage with a Hold rating and a $14 price target. 
This followed a series of updates on April 30th, where Barclays maintained its Equal-Weight rating while raising its price target from $11 to $12. On the same day, UBS held its Neutral rating but increased its price target to a range of $14 to $15.50. Meanwhile, Needham reiterated its Buy rating with a steady $20 price target, suggesting significant upside.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SOFI shares are trading higher by 8.6% to $18.66 Monday morning. The stock has a 52-week high of $18.92 and a 52-week low of $6.01.
Read Also: <a href="https://www.benzinga.com/markets/tech/25/06/46117473/sofi-stock-gets-supercharged-with-return-to-crypto">SoFi Stock Gets Supercharged With Return To Crypto</a>
<h2 class="wp-block-heading">How To Buy SOFI Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in SoFi Technologies&#8217; case, it is in the Financials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Image: Shutterstock

$BTC

SOFI

SoFi Technologies Stock Hits A New 52-Week High: What's Going On?

BMO Capital analyst John McNulty downgrades Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) from Market Perform to Underperform and lowers the price target from $7 to $3.

Downgrades

TROX

BMO Capital Downgrades Tronox Holdings to Underperform, Lowers Price Target to $3

GRRR

Gorilla Technology Group shares are trading lower after the company initiated a $105 million direct stock offering.

Press Releases

Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patients and Providers

Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference

Pulmonx to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Pulmonx to Present at the Citi 2025 Unplugged Medtech and Life Sciences Access Day

Earnings

Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

EDAP Appoints Glen French to Board of Directors

Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

Pulmonx Reports First Quarter 2025 Financial Results

Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference

Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

EDAP

Apyx Medical

Accuray

Anteris Technologies Global Corp. - Common Stock

Anteris Technologies Glb

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

CytoSorbents

CVRx

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

Pulmonx

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL